Back to top
more

Alnylam Pharmaceuticals, Inc. (ALNY)

(Delayed Data from NSDQ)

$132.41 USD

132.41
467,288

+3.78 (2.94%)

Updated May 11, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (221 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for ALNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Alnylam Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 1,874 1,536 1,084 1,691 627
Receivables 602 43 19 34 23
Notes Receivable 0 0 0 0 0
Inventories 75 56 24 0 0
Other Current Assets 63 80 74 40 22
Total Current Assets 2,615 1,716 1,201 1,765 672
Net Property & Equipment 465 425 321 182 115
Investments & Advances 41 15 45 44 475
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 45 18 9 4 2
Total Assets 3,407 2,395 1,575 1,995 1,263
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 52 50 60 28 54
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 356 197 113 72 42
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 141 78 7 44 35
Total Current Liabilities 585 353 179 144 132
Mortgages 0 0 0 0 0
Deferred Taxes/Income 225 318 58 50 58
Convertible Debt 0 0 0 0 0
Long-Term Debt 191 0 30 30 150
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,096 9 5 4 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,391 956 273 228 343
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 5,644 5,201 4,175 3,948 2,610
Retained Earnings -4,585 -3,727 -2,841 -2,148 -1,657
Other Equity -44 -37 -33 -34 -33
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,016 1,439 1,302 1,766 920
Total Liabilities & Shareholder's Equity 3,407 2,395 1,575 1,995 1,263
Total Common Equity 1,016 1,439 1,302 1,766 920
Shares Outstanding 116.10 111.40 101.10 98.30 85.80
Book Value Per Share 8.75 12.91 12.88 17.97 10.73

Fiscal Year End for Alnylam Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 1,710 1,874 1,834 1,926 1,342
Receivables 611 602 579 69 76
Notes Receivable 0 0 0 0 0
Inventories 74 75 67 77 68
Other Current Assets 76 63 75 88 99
Total Current Assets 2,470 2,615 2,555 2,160 1,585
Net Property & Equipment 465 465 445 439 430
Investments & Advances 41 41 25 25 25
Other Non-Current Assets 0 0 0 500 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 43 45 38 20 19
Total Assets 3,255 3,407 3,307 3,374 2,280
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 45 52 28 26 40
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 281 356 295 211 183
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 130 141 125 114 86
Total Current Liabilities 495 585 480 384 339
Mortgages 0 0 0 0 0
Deferred Taxes/Income 208 225 266 282 306
Convertible Debt 0 0 0 0 0
Long-Term Debt 192 191 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,147 1,049 1,027 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,329 2,391 2,092 1,975 930
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 5,747 5,644 5,593 5,520 5,290
Retained Earnings -4,786 -4,585 -4,342 -4,089 -3,909
Other Equity -37 -44 -37 -33 -32
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 926 1,016 1,215 1,400 1,350
Total Liabilities & Shareholder's Equity 3,255 3,407 3,307 3,374 2,280
Total Common Equity 926 1,016 1,215 1,400 1,350
Shares Outstanding 117.50 116.10 116.10 115.30 113.00
Book Value Per Share 7.88 8.75 10.47 12.14 11.94